Equities

Cutia Therapeutics

Cutia Therapeutics

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)7.08
  • Today's Change-0.11 / -1.53%
  • Shares traded388.40k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cutia Therapeutics is a China-based company mainly engaged in the research and development and manufacture of dermatological biological drugs. The Company is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The Company is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The Company conducts its businesses in the domestic market and overseas markets.

  • Revenue in HKD (TTM)148.92m
  • Net income in HKD-2.12bn
  • Incorporated2019
  • Employees298.00
  • Location
    Cutia Therapeutics436 Heng Feng RoadJingan District, 20/F, Huanzhi BuildingSHANGHAI ChinaCHN
  • Websitehttps://www.cutiatx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CStone Pharmaceuticals501.91m-397.37m1.49bn230.00--3.01--2.97-0.315-0.3150.39740.38490.28112.443.722,182,220.00-22.25-54.76-48.85-81.6865.60---79.17-301.621.44--0.4431---3.64--59.32--52.42--
Mabpharm Ltd94.31m-226.54m1.55bn347.00--6.97--16.40-0.0549-0.05490.02290.05380.08930.11766.02271,799.80-21.44-21.42-28.92-27.4986.32---240.19-486.400.7596-19.030.5591--55.87--0.694---26.85--
Jacobio Pharmaceuticals Group Co Ltd68.73m-388.59m1.59bn301.00--1.37--23.15-0.5027-0.50270.08891.470.0419--5.21228,349.70-23.66-45.76-26.86-49.305.04---565.36-372.22----0.1636---33.66--3.43--19.18--
Hua Medicine82.90m-228.57m1.66bn177.00--14.04--19.99-0.2338-0.23380.08480.11180.05381.691.98468,347.90-14.84-25.61-17.56-28.8148.78---275.73-1,654.706.06--0.6238--335.31---3.80------
Immunotech Biopharm Ltd0.00-362.30m1.68bn210.00--8.96-----0.7041-0.70410.000.36510.00----0.00-38.88-37.42-50.88-45.48--------1.03-1.970.4327-------5.25------
Dawnrays Pharmaceutical (Holdings) Ltd1.25bn352.76m1.79bn1.14k5.070.5783.941.430.23470.23470.8292.060.31562.316.371,089,783.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
Cryofocus Medtech Shanghai Co Ltd44.31m-105.49m1.89bn392.00--10.84--42.74-0.4412-0.44120.18530.7307------113,037.90--------75.83---258.23--4.08--0.0597--50.83--13.13------
SinoMab Bioscience Ltd1.48m-263.06m2.00bn233.00--5.92--1,352.66-0.2584-0.25840.00150.3090.0015-------26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---8.150.604------14.45------
Acotec Scientific Holdings Ltd512.74m15.68m2.08bn638.00127.561.4931.714.060.05210.05211.704.480.31360.72133.44803,664.400.9589--1.03--79.65--3.06--9.122.750.1529--19.80---79.35------
Cutia Therapeutics148.92m-2.12bn2.19bn298.00--1.50--14.71-6.99-6.990.48984.80------499,725.10--------51.60---1,426.91--5.38--0.153--1,110.83---253.30------
Abbisko Cayman Ltd20.62m-467.00m2.46bn258.00--1.15--119.17-0.7216-0.72160.03193.050.0083--1.4079,939.16-18.74---19.67--100.00---2,264.34------0.0177------12.92------
Peijia Medical Ltd477.33m-424.74m2.49bn1.04k--1.01--5.21-0.6254-0.62540.70273.620.14730.77739.51458,971.50-13.11-34.08-14.94-36.9073.7671.62-88.99-448.756.92--0.0886--75.86--3.75------
Laekna Inc0.00-399.08m2.52bn89.00--2.90-----3.31-3.310.002.23------0.00-------------------5.280.0655------52.81------
Frontage Holdings Corp2.03bn84.49m2.59bn1.76k31.060.96487.141.270.04090.04090.98141.320.46360.635.321,154,796.001.914.462.335.2830.1734.004.139.921.394.090.2960.003.7925.61-58.00-0.782640.43--
MicroPort CardioFlow Medtech Corp363.81m-510.23m2.70bn592.00--1.07--7.43-0.2159-0.21590.1541.050.12052.783.67614,542.30-16.91-17.37-18.11-22.962.06-1.67-140.25-180.829.91-11.560.0293--33.94---3.77---14.16--
Golden Throat Holdings Group Co Ltd1.04bn270.69m2.78bn869.0010.271.668.892.670.36620.36621.412.270.41814.821.851,197,100.0010.8811.0015.8515.6372.5772.7926.0224.672.4834.740.2183.15-3.096.73-11.0419.61-32.1338.94
Data as of May 10 2024. Currency figures normalised to Cutia Therapeutics's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

10.32%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 22 Mar 202414.19m4.66%
Harvest Global Investments Ltd.as of 09 Jun 20237.16m2.35%
FIL Investment Management (Singapore) Ltd.as of 22 Mar 20247.00m2.30%
FIL Investments Internationalas of 31 Mar 20243.09m1.01%
FIL Investment Advisors (UK) Ltd.as of 31 Oct 20231.00k0.00%
More ▼
Data from 31 Dec 2023 - 03 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.